EM2008E "Treatment of Advanced Hepatocellular Carcinoma: Updates and Unmet Needs" (IM GR-082120)
To review HCC biology, genetics, surveillance, diagnosis, and systemic therapy. This lecture will focus on updates in HCC systemic therapy and provide an overview of immunotherapy resistance mechanisms.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Identify the three main categories of treatment for HCC based on stage: early, intermediate, and advanced.
- Understand that the standard of care for advance HCC is changing rapidly, but that Atezolizumab + bevacizumab, and not sorafenib, is the new standard of care for appropriate patients.
- Understand that immunotherapy resistance is divided into primary and acquired, tumor intrinsic and extrinsic mechanisms.
- Understand that tumor mutational burden is one of many critical intrinsic factors that regulates treatment sensitivity.
Hao Zhu, M.D.
Children’s Research Institute & Department of Internal Medicine
Division of Hematology & Oncology
- 1.00 AMA